ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Ok Marketing Of Taxotere As Treatment For Advanced Breast Cancer

October 20, 1995

Cancer Control Contractors Severally Criticized In Merit Peer Review; Inadequate Reports Cited

May 28, 1976

Limb-Sparing Surgery May Not Offer Better Quality of Life

August 28, 2009

NCAB Considering Concept Review Of Large, Expensive Investigator Initiated Proposals

February 16, 1990

Severe Shortages Of Many Cancer Drugs Affecting Practices

November 19, 2010

Larry Norton Is President-Elect Of ASCO; Rauscher Is Cancer Research Editor-In-Chief.

March 3, 2000